Accordingly, pharmacologic inhibition of glycolysis reduces tumorigenicity of human lung cancer cells bearing KMT2D-inactivating mutations, suggesting that KMT2D deficiency may present a therapeutic vulnerability to glycolytic inhibitors (Ding et al., 2008; Alam et al., 2020). This evidence concerns the gene KMT2D and lung carcinoma.